The Global Diagnostic Antibodies Market is likely to witness numerous growth opportunities with recent advancements in monoclonal antibodies. According to a report by Fortune Business Insights, titled “Diagnostic Antibodies Market Size, Share and Global Trend By Type (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Polyclonal Antibodies), Application (Hepatitis Diagnostics, Tuberculosis Diagnostics, Cancer Diagnostics, Oncology Diagnostics, HIV Diagnostics, Infectious Disease Diagnostics) End User (Hospitals, Diagnostic Centres) and Geography Forecast till 2026,” the growth of this market is likely to take off in the coming years with exceptional advancements in antibody therapeutics.
Some of the leading companies that are operating in the global diagnostic antibodies market are
- Aytu BioScience, Inc.,
- Agilent Technologies, Inc.,
- Boehringer Ingelheim International GmbH,
- Bio-Rad Laboratories, Inc.,
- Abcam plc.,
- Hoffmann-La Roche Ltd.,
- Abbott amongst others.
The use of monoclonal antibodies in the diagnosis and treatment of several diseases have led to a growing emphasis on research and development (R&D) of diagnostic antibodies. Additionally, the contribution from regulatory antibodies in approvals of newer drug applications and methods of diagnosis are likely to favor the growth of the global diagnostic antibodies market in the forthcoming years.
Monoclonal antibodies are used for diagnostic purposes in life-threatening diseases such as cancer. Monoclonal antibodies are developed by cloning of identical immune cells, aimed at generating unique parent cells. The exceptional properties of monoclonal antibodies are likely to result in their use in cancer diagnosis, a reversal of drug toxicity, and may also be useful in diagnosing myocardial infarctions.
Increasing Diagnostic Tools to Offer a Favorable Growth Environment
In 2018, the National Cancer Institute stated that around 1,735,350 cases of cancer were diagnosed in the U.S. The government has identified this as a severe problem and contributed swiftly in the form of cancer awareness programs and health reimbursement policies. Furthermore, there have been increasing approvals from regulatory organizations such as the Food and Drug Organization (FDA) for diagnostic tools for detecting tumor and other forms of cancer.
- Monoclonal Antibodies
- Polyclonal Antibodies
- Recombinant Polyclonal Antibodies
- Hepatitis Diagnostics
- Tuberculosis Diagnostics
- Cancer Diagnostics
- Oncology Diagnostics
- HIV Diagnostics
- Infectious Disease Diagnostics
By End User
- Diagnostic Centres
ImmunoPrecise Receives Subcontract for Manufacture of ‘Rabbit Monoclonal Antibodies’
In 2019, ImmunoPrecise received a subcontract from Leidos Biomedical Research, Inc. for production of rabbit monoclonal antibodies using its B-cell platform. ImmunoPrecise has its own B-Cell select platform that allows screening of large panels of antibodies for functionality testing, thereby allowing to finalize the best possible diagnostic antibody from a host of options. ImmunoPrecise’s latest subcontract and operations may have a positive impact on the global market and their attractive product offerings are likely to favor the growth of the global diagnostic antibodies market in the forthcoming years.
Accounting to this, governments across a few nations are somewhat reluctant in promoting research processes of diagnostic tools and drugs for diagnostic antibodies. Along with the aforementioned factors, lack of healthcare infrastructure in emerging nations is likely to hamper the growth of the global diagnostic antibodies in the coming years.
Additionally, increasing research activities for the development of anti-tumor antibodies are likely to boost the global diagnostic antibodies during the forecast period. Although diagnostic antibodies possess properties to detect several life-threatening diseases, research and studies have also singled out that the questions to some adverse effects still remain unanswered.
Top Treanding Reporsts @